Vis enkel innførsel

dc.contributor.authorRoaldsen, Melinda Berg
dc.contributor.authorEltoft, Agnethe
dc.contributor.authorWilsgaard, Tom
dc.contributor.authorChristensen, Hanne
dc.contributor.authorEngelter, Stefan T.
dc.contributor.authorIndredavik, Bent
dc.contributor.authorJatužis, Dalius
dc.contributor.authorKarelis, Guntis
dc.contributor.authorKõrv, Janika
dc.contributor.authorLundström, Erik
dc.contributor.authorPetersson, Jesper
dc.contributor.authorPutaala, Jukka
dc.contributor.authorSøyland, Mary-Helen
dc.contributor.authorTveiten, Arnstein
dc.contributor.authorBivard, Andrew
dc.contributor.authorJohnsen, Stein Harald
dc.contributor.authorMazya, Michael
dc.contributor.authorWerring, David J
dc.contributor.authorWu, Teddy Y
dc.contributor.authorde Marchis, Gian Marco
dc.contributor.authorRobinson, Thompson G
dc.contributor.authorMathiesen, Ellisiv B
dc.date.accessioned2024-01-26T12:09:04Z
dc.date.available2024-01-26T12:09:04Z
dc.date.issued2022-12-19
dc.description.abstractBackground - Current evidence supports the use of intravenous thrombolysis with alteplase in patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in clinical guidelines. However, access to advanced imaging techniques is often scarce. We aimed to determine whether thrombolytic treatment with intravenous tenecteplase given within 4·5 h of awakening improves functional outcome in patients with ischaemic wake-up stroke selected using non-contrast CT.<p> <p>Methods - TWIST was an investigator-initiated, multicentre, open-label, randomised controlled trial with blinded endpoint assessment, conducted at 77 hospitals in ten countries. We included patients aged 18 years or older with acute ischaemic stroke symptoms upon awakening, limb weakness, a National Institutes of Health Stroke Scale (NIHSS) score of 3 or higher or aphasia, a non-contrast CT examination of the head, and the ability to receive tenecteplase within 4·5 h of awakening. Patients were randomly assigned (1:1) to either a single intravenous bolus of tenecteplase 0·25 mg per kg of bodyweight (maximum 25 mg) or control (no thrombolysis) using a central, web-based, computer-generated randomisation schedule. Trained research personnel, who conducted telephone interviews at 90 days (follow-up), were masked to treatment allocation. Clinical assessments were performed on day 1 (at baseline) and day 7 of hospital admission (or at discharge, whichever occurred first). The primary outcome was functional outcome assessed by the modified Rankin Scale (mRS) at 90 days and analysed using ordinal logistic regression in the intention-to-treat population. This trial is registered with EudraCT (2014–000096–80), ClinicalTrials.gov (NCT03181360), and ISRCTN (10601890).<p> <p>Findings - From June 12, 2017, to Sept 30, 2021, 578 of the required 600 patients were enrolled (288 randomly assigned to the tenecteplase group and 290 to the control group [intention-to-treat population]). The median age of participants was 73·7 years (IQR 65·9–81·1). 332 (57%) of 578 participants were male and 246 (43%) were female. Treatment with tenecteplase was not associated with better functional outcome, according to mRS score at 90 days (adjusted OR 1·18, 95% CI 0·88–1·58; p=0·27). Mortality at 90 days did not significantly differ between treatment groups (28 [10%] patients in the tenecteplase group and 23 [8%] in the control group; adjusted HR 1·29, 95% CI 0·74–2·26; p=0·37). Symptomatic intracranial haemorrhage occurred in six (2%) patients in the tenecteplase group versus three (1%) in the control group (adjusted OR 2·17, 95% CI 0·53–8·87; p=0·28), whereas any intracranial haemorrhage occurred in 33 (11%) versus 30 (10%) patients (adjusted OR 1·14, 0·67–1·94; p=0·64).<p> <p>Interpretation - In patients with wake-up stroke selected with non-contrast CT, treatment with tenecteplase was not associated with better functional outcome at 90 days. The number of symptomatic haemorrhages and any intracranial haemorrhages in both treatment groups was similar to findings from previous trials of wake-up stroke patients selected using advanced imaging. Current evidence does not support treatment with tenecteplase in patients selected with non-contrast CT.<p> <p>Funding - Norwegian Clinical Research Therapy in the Specialist Health Services Programme, the Swiss Heart Foundation, the British Heart Foundation, and the Norwegian National Association for Public Health.en_US
dc.identifier.citationRoaldsen M, Eltoft, Wilsgaard, Christensen, Engelter, Indredavik, Jatužis, Karelis, Kõrv, Lundström, Petersson, Putaala, Søyland, Tveiten, Bivard, Johnsen, Mazya, Werring, Wu, de Marchis, Robinson, Mathiesen. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.. Lancet Neurology. 2022;22(2):117-126en_US
dc.identifier.cristinIDFRIDAID 2100696
dc.identifier.doi10.1016/S1474-4422(22)00484-7
dc.identifier.issn1474-4422
dc.identifier.issn1474-4465
dc.identifier.urihttps://hdl.handle.net/10037/32746
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalLancet Neurology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.subject.hrcsNevrologisk: Legemidler
dc.subject.hrcsNeurological : Pharmaceuticals
dc.subjectVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Nevrologi: 752en_US
dc.subjectVDP::Midical sciences: 700::Clinical medical sciences: 750::Neurology: 752en_US
dc.subjectBehandling / Treatmenten_US
dc.subjectHjerneslag / Cerebral strokeen_US
dc.subjectRandomiserte kontrollerte studier / Randomized controlled studiesen_US
dc.titleSafety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.en_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel